Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

The holy grail of epilepsy prevention: Preclinical approaches to antiepileptogenic treatments
Wolfgang Löscher
Neuropharmacology (2019) Vol. 167, pp. 107605-107605
Closed Access | Times Cited: 124

Showing 1-25 of 124 citing articles:

The Pharmacology and Clinical Efficacy of Antiseizure Medications: From Bromide Salts to Cenobamate and Beyond
Wolfgang Löscher, Pavel Klein
CNS Drugs (2021) Vol. 35, Iss. 9, pp. 935-963
Open Access | Times Cited: 216
30 years of second-generation antiseizure medications: impact and future perspectives
Emilio Perucca, Martin J. Brodie, Patrick Kwan, et al.
The Lancet Neurology (2020) Vol. 19, Iss. 6, pp. 544-556
Closed Access | Times Cited: 183
New epilepsy therapies in development
Pavel Klein, Rafal M. Kaminski, Matthias J. Koepp, et al.
Nature Reviews Drug Discovery (2024) Vol. 23, Iss. 9, pp. 682-708
Closed Access | Times Cited: 28
MicroRNAs as regulators of brain function and targets for treatment of epilepsy
Gary P. Brennan, David C. Henshall
Nature Reviews Neurology (2020) Vol. 16, Iss. 9, pp. 506-519
Closed Access | Times Cited: 128
Repurposed molecules for antiepileptogenesis: Missing an opportunity to prevent epilepsy?
Pavel Klein, Alon Friedman, Mustafa Q. Hameed, et al.
Epilepsia (2020) Vol. 61, Iss. 3, pp. 359-386
Open Access | Times Cited: 86
Single-Target Versus Multi-Target Drugs Versus Combinations of Drugs With Multiple Targets: Preclinical and Clinical Evidence for the Treatment or Prevention of Epilepsy
Wolfgang Löscher
Frontiers in Pharmacology (2021) Vol. 12
Open Access | Times Cited: 84
Impact of predictive, preventive and precision medicine strategies in epilepsy
Rima Nabbout, Mathieu Kuchenbuch
Nature Reviews Neurology (2020) Vol. 16, Iss. 12, pp. 674-688
Closed Access | Times Cited: 77
ATP and adenosine—Two players in the control of seizures and epilepsy development
Edward Beamer, Manvitha Kuchukulla, Detlev Boison, et al.
Progress in Neurobiology (2021) Vol. 204, pp. 102105-102105
Open Access | Times Cited: 72
Levetiracetam Mechanisms of Action: From Molecules to Systems
Itzel Jatziri Contreras‐García, Noemí Cárdenas‐Rodríguez, Antonio Romo‐Mancillas, et al.
Pharmaceuticals (2022) Vol. 15, Iss. 4, pp. 475-475
Open Access | Times Cited: 68
The pharmacological treatment of epilepsy: recent advances and future perspectives
Emilio Perucca
Acta Epileptologica (2021) Vol. 3, Iss. 1
Open Access | Times Cited: 62
Dogs as a Natural Animal Model of Epilepsy
Wolfgang Löscher
Frontiers in Veterinary Science (2022) Vol. 9
Open Access | Times Cited: 40
Epileptogenesis in tuberous sclerosis complex-related developmental and epileptic encephalopathy
Eleonora Aronica, Nicola Specchio, Mark J. Luinenburg, et al.
Brain (2023) Vol. 146, Iss. 7, pp. 2694-2710
Open Access | Times Cited: 37
Microglia in epilepsy
Cheng Yu, Xuejun Deng, Da Xu
Neurobiology of Disease (2023) Vol. 185, pp. 106249-106249
Open Access | Times Cited: 36
Beneficial Effects of Probiotic Bifidobacterium longum in a Lithium–Pilocarpine Model of Temporal Lobe Epilepsy in Rats
О. Е. Зубарева, A. V. Dyomina, Anna A. Kovalenko, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 9, pp. 8451-8451
Open Access | Times Cited: 23
Role of Adenosine in Epilepsy and Seizures
Fabio Tescarollo, Diogo M. Rombo, Lindsay K. DeLiberto, et al.
Journal of Caffeine and Adenosine Research (2020) Vol. 10, Iss. 2, pp. 45-60
Open Access | Times Cited: 56
Opportunities and challenges for microRNA-targeting therapeutics for epilepsy
Gareth Morris, Denis O’Brien, David C. Henshall
Trends in Pharmacological Sciences (2021) Vol. 42, Iss. 7, pp. 605-616
Open Access | Times Cited: 49
Emerging Molecular Targets for Anti-Epileptogenic and Epilepsy Modifying Drugs
Katarzyna Łukasiuk, Władysław Lasoń
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 3, pp. 2928-2928
Open Access | Times Cited: 21
Prevention of epileptogenesis – are we there yet?
Matthias J. Koepp, Eugen Trinka, Wolfgang Löscher, et al.
Current Opinion in Neurology (2024)
Closed Access | Times Cited: 8
The expanding field of genetic developmental and epileptic encephalopathies: current understanding and future perspectives
Nicola Specchio, Marina Trivisano, Eleonora Aronica, et al.
The Lancet Child & Adolescent Health (2024) Vol. 8, Iss. 11, pp. 821-834
Closed Access | Times Cited: 6
No prevention or cure of epilepsy as yet
Pavel Klein, Ivana Tyrlíková
Neuropharmacology (2019) Vol. 168, pp. 107762-107762
Closed Access | Times Cited: 44
Genome-wide microRNA profiling of plasma from three different animal models identifies biomarkers of temporal lobe epilepsy
Gary P. Brennan, Sebastian Bauer, Tobías Engel, et al.
Neurobiology of Disease (2020) Vol. 144, pp. 105048-105048
Open Access | Times Cited: 44
The matrix metalloproteinase inhibitor IPR-179 has antiseizure and antiepileptogenic effects
Diede W. M. Broekaart, Alexandra Bertran, Shaobo Jia, et al.
Journal of Clinical Investigation (2020) Vol. 131, Iss. 1
Open Access | Times Cited: 43
Time to Start Calling Things by Their Own Names? The Case for Antiseizure Medicines
Jacqueline A. French, Emilio Perucca
Epiliepsy currents/Epilepsy currents (2020) Vol. 20, Iss. 2, pp. 69-72
Open Access | Times Cited: 41
Anakinra Reduces Epileptogenesis, Provides Neuroprotection, and Attenuates Behavioral Impairments in Rats in the Lithium–Pilocarpine Model of Epilepsy
A. V. Dyomina, О. Е. Зубарева, Ilya V. Smolensky, et al.
Pharmaceuticals (2020) Vol. 13, Iss. 11, pp. 340-340
Open Access | Times Cited: 40
New approaches for developing multi-targeted drug combinations for disease modification of complex brain disorders. Does epilepsy prevention become a realistic goal?
Wolfgang Löscher, Pavel Klein
Pharmacology & Therapeutics (2021) Vol. 229, pp. 107934-107934
Open Access | Times Cited: 40
Page 1 - Next Page

Scroll to top